Real-world healthcare resource utilization and costs associated with tisagenlecleucel and axicabtagene ciloleucel among patients with diffuse large B-cell lymphoma: an analysis of hospital data in the United States

References

• National Cancer Institute. Cancer Stat Facts: NHL — diffuse large B-cell lymphoma (DLBCL); 2021; [cited 2021 Feb 24]. Available from: https://seer.cancer.gov/statfacts/html/dlbcl.html
   Google Scholar
• Smith A, Howell D, Patmore R, et al. Incidence of haematological malignancy by sub-type: a report from the haematological malignancy research network. Br J Cancer. 2011;105(11):1684–1692.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Nowakowski G, Salles G. Diffuse large B-cell lymphoma: new targets and novel therapies. Blood Cancer J. 2021;11(4):1–10.
   PubMed Web of Science ®Google Scholar
• Friedberg JW. Relapsed/refractory diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program. 2011;2011:498–505.
   PubMed Web of Science ®Google Scholar
• Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the International SCHOLAR-1 study. Blood. 2017;130(16):1800–1808.
   PubMed Web of Science ®Google Scholar
• Hamadani M, Hari PN, Zhang Y, et al. Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014;20(11):1729–1736.
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Schmitz N, Mounier N, et al. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. J Clin Oncol. 2012;30(36):4462–4469.
   PubMed Web of Science ®Google Scholar
• Van Den Neste E, Schmitz N, Mounier N, et al. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the international CORAL study. Bone Marrow Transplant. 2016;51(1):51–57.
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45–56.
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184–4190.
   PubMed Web of Science ®Google Scholar
• Crump M. Management of relapsed diffuse large B-cell lymphoma. Hematol Oncol Clin North Am. 2016;30(6):1195–1213.
   PubMed Web of Science ®Google Scholar
• Crump M, Kuruvilla J, Couban S, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY. 12. J Clin Oncol. 2014;32(31):3490–3496.
   PubMed Web of Science ®Google Scholar
• Sermer D, Batlevi C, Palomba ML, et al. Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies. Blood Adv. 2020;4(19):4669–4678.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Sarkozy C. Diffuse large B-cell lymphoma: R-CHOP failure-what to do? Hematology Am Soc Hematol Educ Program. 2016;2016(1):366–378.
   PubMed Web of Science ®Google Scholar
• Chaganti S, Illidge T, Barrington S, et al. Guidelines for the management of diffuse large B-cell lymphoma. Br J Haematol. 2016;174(1):43–56.
   PubMed Web of Science ®Google Scholar
• Tilly H, Gomes da Silva M, Vitolo U, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl. 5):v116–v125.
   PubMed Web of Science ®Google Scholar
• Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839–852.
   PubMed Web of Science ®Google Scholar
• Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Lancet Oncol. 2019;20(1):31–42.
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531–2544.
   PubMed Web of Science ®Google Scholar
• Mian A, Wei W, Hill BT, et al. Resource utilization and factors prolonging hospitalization for patients with relapsed and refractory large B-cell lymphoma receiving tisagenlecleucel versus axicabtagene ciloleucel. Blood. 2020;136(Suppl. 1):38–39.
   Google Scholar
• Kilgore KM, Mohammadi I, Schroeder A, et al. Medicare patients receiving chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma: a first real-world look at patient characteristics, healthcare utilization and costs. Blood. 2019;134(Suppl. 1):793.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Nguyen A, Snyder S, et al. Economic evaluation of chimeric antigen receptor T-cell therapy by site of care among patients with relapsed or refractory large B-cell lymphoma. JAMA Netw Open. 2020;3(4):e202072.
   PubMed Web of Science ®Google Scholar
• Hernandez I, Prasad V, Gellad WF. Total costs of chimeric antigen receptor T-cell immunotherapy. JAMA Oncol. 2018;4(7):994–996.
   PubMed Web of Science ®Google Scholar
• Yang H, Hao Y, Chai X, et al. Estimation of total costs in patients with relapsed or refractory diffuse large B-cell lymphoma receiving tisagenlecleucel from a US hospital's perspective. J Med Econ. 2020;23(9):1016–1024.
   PubMed Web of Science ®Google Scholar
• Zhao J, Bollu V, Yang H, et al. Healthcare resource use (HRU) by infusion setting of chimeric antigen receptor T-cell (CAR-T) in patients with relapsed and refractory (r/r) diffuse large B-cell lymphoma (DLBCL): a retrospective cohort study using CMS 100% Medicare Database. J Clin Oncol. 2021;39(15 Suppl.):e19550.
   Web of Science ®Google Scholar
• United States Food and Drug Administration (FDA). Highlights of prescribing information: YESCARTA (axicabtagene ciloleucel); 2017; [cited 2021 Feb 24]. Available from: https://www.fda.gov/media/108377/download
   Google Scholar
• United States Food and Drug Administration (FDA). Highlights of prescribing information: KYMRIAH (tisagenlecleucel); 2018; [cited 2019 Oct 28]. Available from: https://www.fda.gov/files/vaccines%2C%20blood%20%26%20biologics/published/Package-Insert---KYMRIAH.pdf
   Google Scholar
• Premier Applied Sciences. Premier Healthcare Database: data that informs and performs [white paper]; 2020; [cited 2021 Sep 1]. Available from: https://products.premierinc.com/downloads/PremierHealthcareDatabaseWhitepaper.pdf
   Google Scholar
• Riedell PA, Walling C, Nastoupil LJ, et al. A multicenter retrospective analysis of outcomes and toxicities with commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed/refractory aggressive B-cell lymphomas. Biol Blood Marrow Transplant. 2020;26(3):S41–S42.
   Web of Science ®Google Scholar
• Pasquini MC, Hu ZH, Curran K, et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020;4(21):5414–5424.
   PubMed Web of Science ®Google Scholar
• Pasquini MC, Locke FL, Herrera AF, et al. Post-marketing use outcomes of an anti-CD19 chimeric antigen receptor (CAR) T cell therapy, axicabtagene ciloleucel (axi-cel), for the treatment of large B cell lymphoma (LBCL) in the United States (US). Blood. 2019;134(Suppl. 1):764.
   Web of Science ®Google Scholar
• Jacobson CA, Locke FL, Hu Z-H, et al. Real-world evidence of axicabtagene ciloleucel (axi-cel) for the treatment of large B-cell lymphoma (LBCL) in the United States (US). J Clin Oncol. 2021;39(15 Suppl.):7552.
   Web of Science ®Google Scholar
• Klink A, Savill K, Liassou D, et al. Real-world treatment with CAR T-cell therapy of United States (US) patients with large B cell lymphoma (LBCL). European Hematology Association Congress (virtual); 2021 Jun 9–19.
   Google Scholar
• Myers GD, Verneris MR, Goy A, et al. Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia. J Immunother Cancer. 2021;9(4):e002056.
   PubMed Web of Science ®Google Scholar
• Harris A, Hohmann S, Epting G, et al. Quality and cost outcomes in chimeric antigen receptor T-cell immunotherapy in adult large B-cell cancer patients from the Vizient Clinical Database. Biol Blood Marrow Transplant. 2020;26(3):S316–S317.
   PubMed Web of Science ®Google Scholar
• Harris A, Hohmann S, Dolan C. Real-world quality and cost burden of cytokine release syndrome requiring tocilizumab or steroids during CAR-T infusion encounter. Biol Blood Marrow Transplant. 2020;26(3):S312.
   Web of Science ®Google Scholar
• Maziarz R, Appel P, Cota B, et al. Abstract #370: financial impact of effector cell therapy on the care of patients with advanced B-cell malignancies. 2021 Transplantation & Cellular Therapy Meeting (virtual); 2021 Feb 8–12.
   Google Scholar
• Jaglowski S, Hu Z-H, Zhang Y, et al. Tisagenlecleucel chimeric antigen receptor (CAR) T-cell therapy for adults with diffuse large B-cell lymphoma (DLBCL): real world experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) cellular therapy (CT) registry. Blood. 2019;134(Suppl. 1):766.
   Google Scholar
• Riedell PA, Brower J, Nastoupil L, et al. A multicenter analysis of outcomes, toxicities, and patterns of use with commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed/refractory aggressive B-cell lymphomas. ASH Annual Meeting; 2021 Dec 11–14; Atlanta, GA; 2021.
   Google Scholar
• Sharma A, Singh V, Deol A. Epidemiology and predictors of readmission in CAR T-cell therapy recipients. Blood. 2021;138(Suppl. 1):3010.
   Google Scholar